Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Tc 99m Tilmanocept Imaging for the Early Prediction of Anti-TNFα Therapy Response in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA)

NCT05246280 is registered in ClinicalTrials.gov with Navidea Biopharmaceuticals as lead sponsor.

NCT NCT05246280
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05246280 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Tc 99m Tilmanocept Imaging for the Early Prediction of Anti-TNFα Therapy Response in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA)
Lead sponsor
Navidea Biopharmaceuticals
Phase
Phase 3
Overall status
Terminated
Start date
March 2, 2022
Completion date
July 9, 2024
Enrollment
169 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis